Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

@article{Chapuis2010PerspectivesOI,
  title={Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies},
  author={Nicolas Chapuis and J{\'e}r{\^o}me Tamburini and Alexa S. Green and Lise Willems and Val{\'e}rie Bardet and Sang-Youel Park and Catherine Lacombe and Patrick Mayeux and Didier Bouscary},
  journal={Leukemia},
  year={2010},
  volume={24},
  pages={1686-1699}
}
Mammalian target of rapamycin (mTOR) is a protein kinase implicated in the regulation of various cellular processes, including those required for tumor development, such as the initiation of mRNA translation, cell-cycle progression and cellular proliferation. In a wide range of hematological malignancies, the mTORC1 signaling pathway has been found to be deregulated and has been designed as a major target for tumor therapy. Given that pre-clinical studies have clearly established the… CONTINUE READING